Biointron Insights: Antibody Industry Trends (Q2 2026 Insights, Trends & Analysis)

Biointron’s Q2 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June. This quarter, six novel antibody drugs have received first approval.

1. Pivekimab Sunirine (Decnupaz)

2. Anbenitamab (恩尼妥)

3. Gumokimab

4. Silevimig

5. Iza-bren

6. Veligrotug (Lumvoa)

Q2 2026 saw many acquisitions, collaborations, and licensing agreements for multiple assets (up to 13 at a time). Significant investment has been directed toward startups developing antibody-drug conjugates (ADCs). Antibody discovery with AI has become a large topic in research, as well as antibody formats such as ATP-switch antibodies.

Gain exclusive insights into current trends such as:

• 6 novel antibody drugs approved for the first time in Q2 2026

• Top 20 antibody drug deals, including M&As, licensing agreements, and collaborations of up to US$15.2B

• Antibody discovery in the AI era, from candidate sequences to model-ready experimental data

• Conditionally activatable antibodies through specific biological or physical cues

• A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q3 2026